Treatment of invasive candidiasis in non-haematological patients
Treatment of invasive candidiasis in non-haematological patients Treatment of invasive candidiasis in non-haematological patients
from sbimc.org
More from this publisher
11.07.2015
Views
Survival in ICU patients:anidulafugin vs fluconazoleKett, Int J Antimicr Ag 2008
Success rates different echinocandinsGlöckner Mycoses2009
- Page 5 and 6: EpidemiologyMainly data from the US
- Page 7 and 8: Survival in candidemia, species rel
- Page 9 and 10: Question1 : Which Candida species i
- Page 11 and 12: Incidence and mortality of Candida
- Page 13 and 14: HOW TO IDENTIFY PATIENTSAT RISK FOR
- Page 15 and 16: Question 2: Which factor has the gr
- Page 17 and 18: Identification of patients“Ostros
- Page 19 and 20: Question3: What’s the problem wit
- Page 21 and 22: Identification of patients“Ostros
- Page 23 and 24: Are the risk predictive models gene
- Page 25 and 26: Question 4: Empirical treatment is
- Page 27 and 28: HOW TO PREVENT INVASIVECANDIDIASIS
- Page 29 and 30: Empirical antifungal therapy in ICU
- Page 31 and 32: TREATMENT OF INVASIVECANDIDIASIS
- Page 33 and 34: Why do we choose whichantifungal dr
- Page 35 and 36: Randomized Non-Inferior TrialsAmB v
- Page 37 and 38: Caspofungin vs. Amphotericin B tria
- Page 39 and 40: Micafungin vs. L-AmB in ICU Patient
- Page 41: Anidulafungin vs. fluconazole study
- Page 45 and 46: Question 5: Should the intravascula
- Page 47 and 48: Antifungal agents and survivalCandi
- Page 49 and 50: In conclusion• Invasive candidias
- Page 51 and 52: Treatment of candidemia-Candida spe
- Page 53 and 54: Success at EIV treatment by pathoge
- Page 55 and 56: Question 6: Should the intravascula
- Page 57 and 58: Candida Scorein practiceProspective
Success rates different ech<strong>in</strong>ocand<strong>in</strong>sGlöckner Mycoses2009
Change language